// App-Quantinova.ai

EP986 : ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA ACCORDING TO PRIOR LINES OF TREATMENT AND REFRACTORY STATUS: IKEMA SUBGROUP ANALYSIS

Researchers

Presenter

  • Meletios-Athanasios Dimopoulos

Principal Investigators

  • Philippe Moreau

  • Bradley Augustson

  • Nelson Castro

  • Tomas Pika

  • Sosana Delimpasi

  • Javier De la Rubia

  • Angelo Maiolino

  • Anthony Reiman

  • Irina Kryuchkova

  • Joaquin Martinez-Lopez

  • Thomas Martin

  • Joseph Mikhael

  • Kwee Yong

  • Marie-Laure Risse

  • Gaelle Asset

  • Sylvia Marion

  • Roman Hajek

Medical Centers

  • Dept. of Hematology/Oncology, Charles University Hospital, Pilsen, Czech Republic,

  • Department of Hematology,University Hospital Hôtel-Dieu,Nantes,France

  • Sanofi R&amp

  • National and Kapodistrian University of Athens, Athens, Greece

  • Hospital de Cancer de Barretos,São Paulo,Brazil

  • Agios,Cambridge,United States

  • Pathology Department, University Hospital La Fe, Valencia, Spain

  • Department of Oncology,Saint John Regional Hospital, Dalhousie University and University of New Brunswick,Saint John,Canada

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Department of Medical Oncology, University College London Hospital, London, United Kingdom

  • Department of Haematooncology, University Hospital Ostrava and the Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic

  • Sir Charles Gairdner Hospital, Perth, Australia

  • D,Chilly-Mazarin,France

  • Instituto COI de Educacao e Pesquisa, Rio De Janeiro, Brazil

  • Department of Haematology,General Hospital of Serres,Serres,Greece

  • Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ

  • Departamento de Hematología,Hospital 12 de Octubre, Complutense University, CNIO,Madrid,Spain

  • Research Institute of Clinical Immunology, Novosibirsk, Russian Federation

  • D,Vitry/Alfortville,France

Locations

  • Czech Republic

  • France

  • Greece

  • Brazil

  • United States

  • Spain

  • Canada

  • United Kingdom

  • Australia

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • carfilzomib Intravenous

  • Isatuximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03275285

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved